Form 4: Beam Therapeutics Director Acquires Stock Options

Director Graham K Cooper acquired 23,114 stock options in Beam Therapeutics Inc. on June 5, 2024.

Summary

• On June 5, 2024, Graham K Cooper, a director of Beam Therapeutics Inc., acquired 23,114 stock options.
• The exercise price of these options is $24.49.
• The options vest on the earlier of June 5, 2025, or immediately prior to the date of the next year's annual meeting of stockholders, contingent upon continued service on the board.
• The options expire on June 5, 2034.
• Following the transaction, Cooper directly owns 23,114 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's acquisition of stock options, which can be seen as a positive sign of confidence but doesn't inherently indicate strong positive or negative sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is contingent upon continued service, suggesting an expectation of ongoing involvement.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency regarding the compensation and equity ownership of company directors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's belief in the company's future prospects.

Key Dates